Ipamorelin dosage numbers belong to their studies.
An amount printed in a paper can look like a treatment plan. It needs its surroundings: the people, the route and the result.

What the researchers gave participants
The human timing study and published surgery trial both gave Ipamorelin into a vein. That route matters whenever their amounts appear elsewhere.
In Gobburu and colleagues’ timing experiment, healthy men received single infusions lasting fifteen minutes. Researchers tested several amounts to measure drug levels and the growth hormone response. They weren’t testing a home treatment plan.
In Beck’s published surgery trial, participants in the active group received 0.03 mg/kg intravenously twice a day from the day after surgery until discharge, for up to seven days. The comparison group received placebo. The trial did not show a statistically convincing benefit on its main meal-tolerance measure.
Those are facts about experiments. They don’t recommend an amount, a frequency or a treatment length for anyone reading this page.
The half-life cannot do the prescribing
Healthy men receiving infusions supplied the roughly two-hour Ipamorelin half-life estimate. It describes falling blood levels, not the right time for another dose.
A treatment plan would need evidence about the intended benefit, preparation, route and safety. It would also need an individual assessment. Dividing a time interval or changing a unit doesn’t supply any of that missing information.
FDA found no human data on drug levels or hormone response for the proposed under-skin route. An under-skin injection has to be absorbed before reaching the blood. Borrowing the vein-study number skips that step and the missing data.
The same limit applies to cycle length. A hormone response does not establish how long a treatment is useful or safe.
The useful questions are bigger than the number
What health problem is being assessed? What evidence supports a benefit, and what alternatives are available? Those questions need answers before a study amount becomes relevant.
Preparation and regulation matter, too. FDA’s safety entry has an April 22, 2026 content date. The acetate form has a Category 2 entry for 503B outsourcing facilities. For 503A pharmacy compounding, the entry says the nomination was withdrawn. Withdrawal gives no clearance or approval to compound.
A licensed clinician can review the person’s history, the proposed route and the uncertainty. A request may be declined. State and treatment limits still apply; the existence of a prescription option doesn’t settle the preparation’s legal position or establish a benefit.
Read the safety discussion alongside any study regimen. The amount is only one part of what happened in that experiment.